Merck signs up to $2 bln obesity drug deal with Chinese biotech HansohDec 18 (Reuters) - U.S. drugmaker Merck MRK.N on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals 3692.HK to develop and commercialize the Chinese biotech's obesity drug.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments